Tracking cancer cells after chemoradiation for oral cancer
Part of Cancer, Mouth & dental clinical trials.
This trial studies whether detecting circulating tumor cells in the blood after chemoradiation can help predict outcomes for people with oral cancer that has spread to lymph nodes. It may help doctors better monitor the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 90 years old.
- You have squamous cell carcinoma of the head and neck, such as oral cancer.
- You had surgery and it showed high-risk features like cancer spread outside lymph nodes.
- You completed chemoradiation after surgery.
- You are willing to come back to the hospital for follow-up appointments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study aims to find signs of head and neck cancer coming back early, using scans/tests after you’ve had radical treatment. If you’re at higher risk and HPV-negative, this may help doctors catch relapse sooner.
This study looks for early “biomarkers” (signals in blood or tissue) to see how well head and neck cancer treatments are working over time. It may help doctors adjust treatment sooner based on those early signals.
This study looks at whether certain blood tests can help predict how head and neck cancer will respond to treatment. If you are planning surgery for squamous cell cancer of the throat, voice box, or mouth, this trial may offer more information about your outlook.
This trial is testing a new blood test (called a liquid biopsy) to better understand and predict the course of head and neck cancers that have come back or spread. If you join, researchers will use a special chip to look at your immune cells and tumor cells in your blood.
This study uses a blood test to see whether cancer DNA is still detectable after a stronger combination of radiation and chemotherapy for locally advanced head and neck cancer. The goal is to predict who may have “residual” (remaining) disease and help guide future care.
This study looks for cancer DNA left in the body after standard chemoradiation for advanced head and neck squamous cell cancer. It aims to understand if this residual DNA means the disease is more likely to come back.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.